IRRAS AB

79 articles about IRRAS AB

• IRRAS AB publishes Year End Report for the period January to December 2022

  2/16/2023

  Q4 2022 marked the conclusion of a transformational year for IRRAS, and, as we begin the new year, we have created new opportunities that will accelerate our growth toward achieving leadership in the world of neurocritical care.

• IRRAflow System Confirmed to More Effectively Remove Collected Blood and Reduce Catheter Infection Rates than Passive Drainage in Head-to-Head Analysis

  2/13/2023

  IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced that the publication of the first comparative study detailing the use of the company's novel IRRAflow system.

• IRRAS Receives US FDA 510(k) Clearance for its Next Generation IRRAflow Control Unit

  12/12/2022

  IRRAS announced that it received regulatory clearance from the United States Food, Drug, and Administration to active all of the functionality on the next generation control unit for its flagship product, IRRAflow, the world's first and only active fluid exchange system.

• IRRAS Announces Commercial Partnership with Medtronic in the United States for its IRRAflow® System

  11/14/2022

  IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced it has signed a Sales Agency Agreement to promote its IRRAflow system in the United States with Medtronic, a global leader in healthcare technology.

• IRRAS AB publishes Interim Report for the period January to September 2022

  11/10/2022

  IRRAS announced and completed a fully subscribed rights issue that raised MSEK 215 before deduction of costs related to the transaction.

• IRRAS Announces Participation and Data Presentation at the 22nd European Congress of Neurosurgery

  10/13/2022

  IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced it will be exhibiting at EANS 2022, the 22nd European Congress of Neurosurgery, hosted by the European Association of Neurological Societies.

• IRRAS Announces New Educational Webinar Series in Collaboration with the Jacobs Institute and the University of Buffalo Department of Neurosurgery

  10/11/2022

  IRRAS announced the launch of a new educational webinar series, 'Exploring the Impact of IRRAflow's Active Fluid Exchange: Our Early Experience Utilizing IRRAflow for Intracranial Hemorrhage', with the Jacobs Institute.

• IRRAS Announces Participation and Educational Symposium at Key Upcoming Neurosurgery Conferences

  10/5/2022

  IRRAS announced its plans to participate in the upcoming annual meetings of the Congress of Neurological Surgeons in San Francisco, CA, from October 8 - 12, 2022, and the Neurocritical Care Society in San Antonio, TX, from October 17 - 21, 2022.

• IRRAS Announces First Patient Treatments at Mount Sinai Health System in New York as Part of the DIVE Study

  8/23/2022

  IRRAS announced the initial patient treatments with the company's IRRAflow system within Mount Sinai Health System in New York, NY, one of the United States' largest and most respected hospital groups.

• IRRAS AB publishes Interim Report for the period January to June 2022

  7/22/2022

  The second quarter of 2022 provided the latest data point to confirm IRRAS' progress toward becoming a leader in neurocritical care.

• IRRAS Announces publication of a Case report from Buffalo General Medical Center, highlights clinical superiority of IRRAflow treatment versus traditional drainage

  5/28/2021

  Publication also documents the ability to deliver targeted thrombolytic medication via IRRAflow's recurring irrigation for the first time in peer-reviewed scientific literature

• IRRAS Announces Notified Body Transition from GMED to DEKRA, a Global Leader in Inspection and Certifications

  5/11/2021

  IRRAS AB, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced that the CE Mark certificates for its IRRAflow system and the company's ISO13485:2016 certification have been transferred to a new notified body, DEKRA.

• IRRAS AB publishes Interim Report for the period January to March 2021

  5/4/2021

  During Q1, the global installed base for IRRAS products increased; the total number of IRRAflow systems increased from 73 to 84 and Hummingbird systems grew from 5 to 9.

• IRRAS Promotes Will Martin to Chief Executive Officer

  4/21/2021

  IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced that its Board of Directors has appointed Will Martin as President and Chief Executive Officer of the Company.

• IRRAS Announces Collaboration with Aarhus University Hospital, Scandinavian Leader in Neurosurgery, to Advance Use of IRRAflow

  4/6/2021

  The collaboration with Aarhus University's neurosurgical team will evaluate IRRAflow during the treatment of Intraventricular Hemorrhage (IVH) and assessment of brain compliance

• IRRAS publishes annual report for 2020

  3/30/2021

  IRRAS's annual report 2020 has been published on the company's website.

• IRRAS to Present at Redeye

  3/23/2021

  IRRAS, a global healthcare company with a comprehensive portfolio of innovative products for neurocritical care, announced that company management will present at the Swedish Investment Bank Redeye on March 30 at 4:00 pm-5:00pm CET.

• IRRAS Announces the recruitment of Sten Gustafsson as Director of Investor Relations

  3/9/2021

  IRRAS, a global healthcare company with a comprehensive portfolio of innovative products for neurocritical care, announced that the hiring of Sten Gustafsson as Director of Investor Relations, reporting directly to the company's Chief Financial Officer, Sabina Berlin.

• IRRAS AB publishes Year End Report for the period January to December 2020

  2/16/2021

  During the course of the 4th quarter, challenges associated with the COVID-19 global pandemic increased and impacted the company's commercial activity.

• Q4 Report 2020 - invitation to conference call and audiocast

  2/9/2021

  On Tuesday February 16, at 16.00 CET, IRRAS will host a conference call and an online presentation of its Q4 2020 interim report.